Compare iShares China Large-Cap ETF (FXI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Tango Therapeutics Inc. — how do they compare? iShares China Large-Cap ETF trades at $33.72 (market cap $3.93B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares China Large-Cap ETF and Tango Therapeutics Inc. are close in size by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 151 Days and Tango Therapeutics Inc. for 0 Days on average.
| FXI | TNGX | |
|---|---|---|
Market Cap | $3.93B | $3.75B |
Volume | 14,707,409 | 9,619,106 |
52-Week High | $41.08 | $32.90 |
52-Week Low | $31.59 | $7.50 |
Typical Hold Time | 151 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI, the iShares China Large-Cap ETF, trades at $34.17 with minimal daily movement (+0.09%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. Recent news highlights China's mixed economic signals, including strong corporate profit growth but concerns over industrial overcapacity and trade tensions. The ETF offers value exposure with a P/E ratio approximately half that of the S&P 500, but faces significant geopolitical and economic headwinds.
The outlook for FXI remains clouded by US-China relations and domestic economic challenges. Investment opportunity lies in its valuation discount versus US equities and potential policy support from Chinese authorities. Key risks include escalating trade protectionism, weak domestic consumption, and regulatory uncertainty. Analyst sentiment is divided, reflecting the high-risk, high-reward nature of Chinese large-cap exposure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
